Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Dow Jones futures rose solidly early Wednesday, along with S&P 500 futures and Nasdaq futures. The CPI inflation report is due before the open.The stock market reversed sharply lower Tuesday morning ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Verona Pharma (VRNA – Research Report). The company’s ...

BTIG analyst Mark Massaro lowered the firm’s price target on MaxCyte (MXCT) to $6 from $8 and keeps a Buy rating on the shares after its Q4 ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). In a filing disclosed on March 09th, the Representative disclosed that they had ...

AbbVie, Danaher, Thermo Fisher Scientific, Cognizant Technology Solutions, and Vertex Pharmaceuticals are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech ...

The Invesco QQQ ETF, which tracks the Nasdaq 100 index, has crashed this year and moved into a correction after falling by ...

Vertex Pharmaceuticals has dominated the cystic fibrosis (CF) market and is now expanding into new, high-growth areas. The ...

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

The cell-based product is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy that was FDA-OK'd and launched in 2023.